Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idroxioleic acid - Laminar Pharmaceuticals

Next Previous
Drug Profile

Idroxioleic acid - Laminar Pharmaceuticals

Alternative Names: 2-hydroxy-9-cis octadecenoic - Laminar Pharmaceuticals; 2-Hydroxyoleic acid - Laminar Pharmaceuticals; 2-OHOA - Laminar Pharmaceuticals; LAM-561; LP561A1; Minerval

Latest Information Update: 14 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of the Balearic Islands
  • Developer Dana-Farber Cancer Institute; Hackensack Meridian Health; Laminar Pharmaceuticals
  • Class Anorectics; Antineoplastics; Oleic acids
  • Mechanism of Action Furin inhibitors; Notch signalling pathway inhibitors; Phosphatidylcholine ceramide phosphocholine transferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Glioblastoma
  • Phase I/II Glioma; Solid tumours

Most Recent Events

  • 05 Mar 2025 Idroxioleic acid - Laminar Pharmaceuticals is available for licensing as of 05 Mar 2025. www.laminarpharma.com
  • 05 Mar 2025 Efficacy and adverse events data from a phase IIb/III CLINGLIO trial for Glioblastoma released by Laminar Pharmaceuticals
  • 11 Jun 2024 Laminar Pharmaceuticals announces intention to submit regulatory filings for full marketing authorization to EMA for Glioblastoma in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top